Cutting edge single gene test now available
What is Embryo Genetic Testing?
Embryo Genetic Testing includes Preimplantation Genetic Diagnosis (PGD) and Preimplantation Genetic Screening (PGS). Both the diagnosis and screening tests are options for couples at increased risk of passing a chromosome abnormality or specific genetic disorder on to their children. Couples choose PGD and PGS for many reasons, including repeat implantation failure, repeat miscarriage or loss of a child from a genetic disease.
Monash IVF offer a comprehensive suite of Preimplantation Genetic Screening (PGS) including Embryo Screen and Preimplantation Genetic Diagnosis (PGD) using Karyomapping a new single gene test now available in-house. Karyomapping is suitable for patients with a family history of a single gene disorder who are at risk of producing embryos that are affected by that single gene disorder including Cystic Fibrosis, Fragile X, Beta-thalassaemia or Spinal Muscular Atrophy.
What are the benefits of Karyomapping?
Karomapping offers several significant benefits including:
- A significant reduction in the timeframe required to perform the test. As the testing is performed on a standardised platform, there is no need to tailor design a specific test for each couple. As a result, the turnaround time for testing is only 2-4 weeks.
- Karyomapping has the potential to detect some chromosome abnormalities which may be associated with implantation failure, miscarriage, or abnormalities at birth. While the testing is not specifically designed to screen for chromosome abnormalities and there is no guarantee that all chromosome abnormalities will be detected, this does represent a significant improvement compared to previous testing.
- Karyomapping is more cost effective. This testing is charged at $770 per biopsied embryo, with the fee capped at $4,110 per PGD cycle
To learn more about Karyomapping please call us on 1800 628 533 (freecall) or complete the enquiry form below.
Learn more about our suite of Embryo Genetic Testing here